查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010933

卵巢癌治疗市场：2026-2032年全球市场预测（按癌症类型、治疗方法、药物分类、给药途径、分销管道和最终用户划分）

Ovarian Cancer Drugs Market by Cancer Type, Treatment Type, Therapeutic Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，卵巢癌治疗市场价值将达到 51.3 亿美元，到 2026 年将成长至 58 亿美元，到 2032 年将达到 129.4 亿美元，复合年增长率为 14.12%。

主要市场统计数据
基准年 2025 51.3亿美元
预计年份：2026年 58亿美元
预测年份 2032 129.4亿美元
复合年增长率 (%) 14.12%

对重塑卵巢癌治疗路径和相关人员优先事项的系统性因素进行了清晰的概述，包括治疗和诊断技术的进步。

卵巢癌治疗已进入一个变革时期，这主要得益于标靶治疗、免疫肿瘤学和优化化疗方案的进步。本文将全面概述治疗方法，重点关注临床进展、监管变化以及影响研究、临床实践和商业整体情况决策的许多因素。

详细分析精准医疗、适应性临床试验设计和不断发展的支付方框架如何重新定义卵巢癌治疗的采用和发展策略。

卵巢癌的治疗格局正在经历一场变革，这主要得益于分子水平表征的进步、标靶治疗日益增长的关注，这些联合治疗旨在扩大临床获益。精准医学的进步使得利用实用生物标记对患者进行分层成为可能，从而提高了标靶DNA修復缺陷和血管生成通路药物的临床效用。这促使人们更加关注开发治疗方法直接影响肿瘤生物学特性或增强免疫介导的肿瘤控制的治疗方法。

对 2025 年价格趋势将如何重塑整个卵巢癌治疗价值链的供应链、采购行为和策略性成本降低方法进行严格评估。

美国2025年实施的新关税措施，为癌症治疗领域的製药企业和经销商的供应链规划和成本管理带来了新的复杂性。与关税相关的原料药、关键原料和成品药进口成本基础的调整，可能在采购、生产和分销的各个环节造成压力。这促使製造商重新评估其供应商布局，考虑将关键零件的生产转移到国内或附近地区，并寻求更高的垂直整合度，以降低关税波动带来的风险。

基于全面细分的洞察，将疾病亚型、治疗机制、给药途径、分销管道和医疗保健环境与策略研发和商业化选择联繫起来。

对卵巢癌治疗市场进行精细细分，揭示了不同疾病亚型、治疗方法、给药机制、分销管道和医疗机构在临床和商业性趋势上的差异。以癌症类型划分，本检验了上皮性卵巢癌、生殖细胞肿瘤、小细胞卵巢癌和间质细胞肿瘤的市场模式。每种癌症都具有独特的生物学特征、诊断挑战和治疗反应，这些都会影响研发重点和临床试验设计。按治疗方法，本分析涵盖了化疗、荷尔蒙疗法、免疫疗法、放射线治疗和标靶治疗，并重点关注联合治疗和治疗顺序策略如何优化患者疗效和提高商业性可行性。

从策略区域分析的角度解释主要全球区域的监管、支付方和临床基础设施特征如何影响开发和准入策略。

区域趋势显着影响卵巢癌治疗药物的研发重点、监管策略和商业化路径。在美洲，临床试验能力、支付方的专业知识以及成熟的肿瘤学网络，共同创造了一个有利于新药快速推广的环境，而这些新药的推广是基于可靠的临床疗效和成本效益证据。儘管该地区与监管机构的互动往往侧重于明确的临床终点和全面的安全性评估，但与支付方的谈判通常侧重于基于疗效的条件以及提供额外数据等方面的协议。

详细的公司趋势显示，成熟公司、生物技术创新者、契约製造製造商和诊断合作伙伴正在调整其策略，以推进卵巢癌治疗的发展。

卵巢癌治疗领域的公司层面趋势反映出，成熟的跨国製药公司、灵活的生物技术创新者、契约製造组织和专业诊断服务提供者之间存在着持续性。大型製药企业通常会利用其丰富的临床开发资源、与全球监管机构谈判的经验以及广泛的商业网络来支持后期研发项目和联合治疗。它们的优先事项通常包括生命週期管理以保持竞争优势、拓展适应症以及整合伴随诊断。

决策者面临的可操作的策略挑战是，如何协调临床差异化、供应弹性和支付方参与，以实现可持续的市场进入和推广。

产业领导者应优先考虑整合临床开发、供应链韧性和支付方合作的综合方法，以确保并扩大卵巢癌治疗的可及性。早期投资生物标记计画和伴随诊断可提高在目标族群中证实具有临床意义的益处的可能性，并有助于获得更有利的报销谈判结果。同时，将真实世界证据的收集纳入核准后计划，可增强价值主张，并在适当情况下支持基于结果的合约。

透明且可重复的研究途径，结合文献综述、专家访谈和交叉检验，确保了可靠的临床和商业性结果。

本执行摘要的调查方法结合了系统性的证据整合、定性专家对话以及对公开临床和监管资讯的三角检验。主要资讯来源包括同侪审查的临床文献、监管申报文件、临床试验註册资讯以及来自重要肿瘤学会议的结果数据。除上述资讯来源外，我们还对临床研究人员、医保报销专家和商业领域领导者进行了结构化访谈，以确定实施过程中的实际考虑、准入障碍和市场趋势。

简明扼要地整合了治疗方法进展、获取挑战以及为在整个医疗保健系统中实现临床获益和永续获取所需的协作努力。

总之，卵巢癌治疗生态系在取得重大科学进展的同时，也面临着巨大的商业性和营运复杂性。标靶治疗、免疫肿瘤学方法和诊断技术的进步为改善患者预后创造了机会，但这些机会受到支付方预期、供应链现实以及区域间医疗资源分配不均等因素的限制。能够将临床开发与切实可行的准入计划和稳健的生产策略相结合的相关人员，将更有能力将创新转化为可持续的患者获益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以癌症类型分類的卵巢癌治疗市场

  • 上皮性卵巢癌
  • 生殖细胞肿瘤
  • 小细胞卵巢癌
  • 间质瘤

第九章：依治疗方法分類的卵巢癌治疗市场

  • 化疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 放射线治疗
  • 分子标靶治疗

第十章：依疗法分类分類的卵巢癌治疗市场

  • 血管新生抑制剂
  • PARP抑制剂
  • PD-L1抑制剂

第十一章卵巢癌治疗药物市场：依给药途径划分

  • 静脉注射
  • 口服

第十二章卵巢癌治疗药物市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章卵巢癌治疗药物市场：依最终用户划分

  • 癌症中心
  • 诊所
  • 医院

第十四章卵巢癌治疗药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章卵巢癌治疗药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章卵巢癌治疗药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国卵巢癌治疗市场

第十八章：中国卵巢癌治疗药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • Aravive, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Clovis Oncology, Inc.
  • Compugen Ltd.
  • GlaxoSmithKline plc
  • ImmunoGen, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Oncxerna Therapeutics, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sutro Biopharma, Inc.
  • Tesaro, Inc.
  • Zentalis Pharmaceuticals, Inc.
Product Code: MRR-434CCDA052A2

The Ovarian Cancer Drugs Market was valued at USD 5.13 billion in 2025 and is projected to grow to USD 5.80 billion in 2026, with a CAGR of 14.12%, reaching USD 12.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.13 billion
Estimated Year [2026] USD 5.80 billion
Forecast Year [2032] USD 12.94 billion
CAGR (%) 14.12%

A clear contextual overview of therapeutic progress, diagnostic advances, and systemic forces reshaping ovarian cancer treatment pathways and stakeholder priorities

The management of ovarian cancer has entered an era of substantive therapeutic evolution, with advances spanning targeted therapies, immuno-oncology, and optimized chemotherapeutic regimens. This introduction frames the current therapeutic landscape by emphasizing clinical progress, regulatory shifts, and the broader drivers shaping decision-making across research, clinical practice, and commercial strategy.

Emerging biologics, precision-targeted agents, and evolving standards of care have redefined clinical pathways for many ovarian cancer subtypes. Concurrently, improvements in diagnostic sensitivity, biomarker stratification, and combination regimen design have elevated the expectations for patient outcomes. As stakeholders contend with a complex interplay of innovation, access, and affordability, understanding these dynamics is essential for effective portfolio prioritization and resource allocation.

This section lays the groundwork for the deeper analysis that follows, focusing on how clinical advances intersect with payer dynamics, supply chain considerations, and evolving patient-centric models of care. By establishing this context, readers are positioned to interpret subsequent insights on competitive shifts, segmentation-level nuances, and region-specific implications with greater clarity and strategic relevance.

An in-depth exploration of how precision medicine, adaptive clinical design, and evolving payer frameworks are redefining adoption and development strategies in ovarian cancer therapeutics

The ovarian cancer drug landscape is experiencing transformative shifts driven by improved molecular characterization, the maturation of targeted modalities, and a growing emphasis on combination strategies that extend clinical benefit. Precision medicine advances have enabled the stratification of patients by actionable biomarkers, thereby increasing the clinical utility of agents designed to exploit DNA repair deficiencies and angiogenesis pathways. This has led to an accelerated focus on developing therapies that either directly target tumor biology or enhance immune-mediated tumor control.

Parallel to therapeutic innovation, trial design has evolved to incorporate adaptive protocols, biomarker-enriched cohorts, and surrogate endpoints that expedite evaluation without compromising scientific rigor. Regulatory agencies are increasingly open to expedited pathways for agents that demonstrate meaningful clinical improvement in well-defined populations, which in turn is changing sponsor development strategies and commercialization timelines.

Commercially, payers and providers are responding to these clinical shifts with more nuanced coverage approaches that emphasize value-based contracting, real-world evidence generation, and outcomes-based agreements. In practice, this has incentivized manufacturers to invest in post-approval studies, health economics and outcomes research, and stakeholder engagement programs to support formulary access. Taken together, these shifts are not only altering the therapeutic arsenal available to clinicians but also redefining how success is measured and how therapies are adopted within health systems.

A rigorous assessment of how 2025 tariff dynamics are reshaping supply chains, procurement behavior, and strategic cost mitigation approaches across the ovarian cancer therapeutic value chain

The introduction of new tariff measures in the United States in 2025 has injected fresh complexity into supply chain planning and cost management for pharmaceutical manufacturers and distributors involved in oncology therapeutics. Tariff-related adjustments to the cost base of active pharmaceutical ingredients, critical raw materials, and finished drug imports can create pressure points across procurement, manufacturing, and distribution. This has prompted manufacturers to re-evaluate supplier footprints, to consider onshoring or nearshoring of key components, and to explore greater vertical integration to mitigate exposure to tariff volatility.

For healthcare providers and payers, tariff-driven cost shifts translate into potential changes in procurement strategies and formulary negotiations. Hospitals and cancer centers may respond by optimizing inventory management, prioritizing therapeutics with more secure supply chains, and engaging in multi-year purchasing agreements to lock in pricing. Simultaneously, manufacturers face increased scrutiny to demonstrate value through clinical differentiation or service offerings that justify any upward pressure on net prices.

From a strategic vantage, organizations that proactively model tariff scenarios, diversify supplier networks, and incorporate contingency clauses into contracts will be better positioned to sustain continuity of care. Moreover, real-world evidence and pharmacoeconomic data become even more critical levers when justifying access decisions in an environment of heightened cost transparency and supply uncertainty. Ultimately, the cumulative impact of tariffs is less about a single cost increase and more about how it reshapes strategic priorities across R&D sourcing, manufacturing location decisions, and commercial access tactics.

Comprehensive segmentation-driven insights linking disease subtypes, therapeutic mechanisms, administration routes, distribution channels, and care settings to strategic R&D and commercialization choices

A nuanced segmentation of the ovarian cancer therapeutics market reveals differentiated clinical and commercial dynamics across disease subtype, treatment modality, therapeutic mechanism, mode of administration, distribution route, and care setting. Based on Cancer Type, the landscape is examined across Epithelial Ovarian Cancer, Germ Cell Tumors, Small Cell Ovarian Cancer, and Stromal Cell Tumors, each presenting unique biological characteristics, diagnostic challenges, and therapeutic responsiveness that influence development priorities and clinical trial designs. Based on Treatment Type, analyses explore Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, and Targeted Therapy, with specific attention to where combination regimens or sequencing strategies can optimize patient outcomes and commercial viability.

Based on Therapeutic Class, the review details Angiogenesis Inhibitors, PARP Inhibitors, and PD-L1 Inhibitors, highlighting distinct mechanisms of action, biomarker dependencies, and resistance pathways that shape clinical utility. Based on Route Of Administration, contrasts between Intravenous and Oral delivery are explored, including implications for adherence, outpatient care utilization, and cost components associated with administration. Based on Distribution Channel, insights consider Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy dynamics, with an emphasis on how channel mix affects patient access, reimbursement pathways, and logistics. Based on End User, the report evaluates Cancer Centers, Clinics, and Hospitals, recognizing differences in treatment protocols, procurement capabilities, and capacity to deliver complex regimens.

Interpreting these segmentation lenses in concert reveals where incremental innovation, improved diagnostics, or delivery optimization can most substantially influence outcomes and adoption. For stakeholders, segmentation clarity supports targeted development plans, differentiated go-to-market strategies, and more precise health economics evidence generation tailored to the needs of distinct patient cohorts and care settings.

A strategic regional analysis describing how distinct regulatory, payer, and clinical infrastructure characteristics in major global regions affect development and access strategies

Regional dynamics exert a profound influence on development priorities, regulatory strategy, and commercialization pathways for ovarian cancer therapeutics. In the Americas, clinical trial capacity, payer sophistication, and established oncology networks create an environment conducive to rapid uptake of novel agents, contingent on robust evidence of clinical benefit and cost-effectiveness. Regulatory interactions in this region tend to favor clear clinical endpoints and comprehensive safety profiling, while payer negotiations frequently center on outcomes-based terms and supplemental data commitments.

In Europe, Middle East & Africa, diversity in regulatory frameworks and payer systems necessitates tailored market access plans that account for national HTA processes, varying reimbursement thresholds, and heterogeneity in clinical infrastructure. Countries within this region can move at different paces; therefore, parallel regulatory strategies and phased dossier submissions are common approaches to optimize launch sequencing and resource allocation.

In Asia-Pacific, high-growth healthcare investments, expanding clinical trial ecosystems, and increasing domestic manufacturing capabilities are key market drivers. Regulatory harmonization efforts and accelerating approvals for oncology indications in several APAC jurisdictions have created opportunities for earlier entry, particularly when local evidence generation or bridging studies support regional applicability. Each region's infrastructure, reimbursement mechanisms, and patient pathway nuances must be integrated into a comprehensive go-to-market strategy to ensure clinical adoption and sustainable access.

Detailed corporate insights illustrating how incumbents, biotech innovators, contract manufacturers, and diagnostics partners are aligning strategies to advance ovarian cancer therapies

Company-level dynamics in the ovarian cancer therapeutics arena reflect a continuum between established multinational pharmaceutical firms, nimble biotechnology innovators, contract manufacturing organizations, and specialized diagnostics providers. Large pharmaceutical companies typically leverage broad clinical development resources, global regulatory experience, and extensive commercial networks to support late-stage assets and combination regimens. Their priorities often include lifecycle management, label expansions, and the integration of companion diagnostics to sustain competitive advantage.

Biotechnology firms and clinical-stage innovators frequently focus on mechanism-driven differentiation, early biomarker validation, and strategic partnerships that enable accelerated pathways to market. These entities are also more likely to engage in alliance-based approaches, leveraging co-development, licensing, or co-commercialization agreements to scale clinical programs and de-risk late-stage investment. Contract and specialty manufacturers play a critical role in ensuring supply continuity, addressing capacity constraints, and supporting formulation innovation that may enable more convenient routes of administration.

Diagnostics companies and digital health vendors contribute critical capabilities for patient selection, monitoring, and real-world evidence generation. Their tools enhance trial efficiency and support post-approval evidence needs that are increasingly demanded by regulators and payers. Overall, company strategy is converging toward collaborative models that align therapeutic innovation with diagnostic precision and commercial agility to address the multifaceted challenges of advancing ovarian cancer care.

Actionable strategic imperatives for decision-makers to harmonize clinical differentiation, supply resilience, and payer engagement for durable market access and uptake

Industry leaders should prioritize an integrated approach that aligns clinical development, supply chain resilience, and payer engagement to secure and expand access for ovarian cancer therapeutics. Early investment in biomarker programs and companion diagnostic development will increase the probability of demonstrating clinically meaningful benefit in targeted populations and will facilitate more favorable reimbursement discussions. Simultaneously, embedding real-world evidence generation into post-approval plans will reinforce value arguments and support performance-based contracting where appropriate.

From an operational perspective, diversifying supplier networks and exploring regional manufacturing options can mitigate tariff and geopolitical risks while shortening lead times and improving responsiveness to demand fluctuations. Commercially, developing differentiated service offerings-such as adherence support, patient navigation, and comprehensive data dashboards for clinicians and payers-can strengthen product positioning beyond clinical efficacy alone. Finally, forging strategic alliances with diagnostics providers, health systems, and patient advocacy groups will help to accelerate adoption, inform clinical guidelines, and ensure that treatment pathways reflect both efficacy and patient-centered outcomes.

A transparent and replicable research approach integrating literature synthesis, expert interviews, and cross-validation to ensure robust clinical and commercial insights

The research methodology underpinning this executive summary combines systematic evidence synthesis, qualitative expert engagement, and triangulation of publicly available clinical and regulatory information. Primary inputs include peer-reviewed clinical literature, regulatory filings, trial registries, and outcome data from recognized oncology conferences. These sources are complemented by structured interviews with clinical investigators, reimbursement specialists, and commercial leaders to surface practical considerations around adoption, barriers to access, and landscape dynamics.

Analytical processes involve mapping therapeutic mechanisms to clinical endpoints, assessing the implications of administration routes and distribution channels on adoption, and evaluating payer and provider decision drivers across regions. Validation steps include cross-referencing trial outcomes with regulatory decisions and consulting clinical experts to ensure interpretive accuracy. Where gaps exist, targeted follow-up interviews and scenario modeling are employed to clarify likely operational and strategic impacts, ensuring that conclusions are robust, actionable, and clinically grounded.

A concise synthesis of therapeutic advancements, access challenges, and collaborative actions required to realize clinical benefit and sustainable access across healthcare systems

In conclusion, the ovarian cancer therapeutic ecosystem is characterized by meaningful scientific progress alongside material commercial and operational complexity. Advances in targeted therapies, immuno-oncology approaches, and diagnostics have created opportunities to improve patient outcomes, yet those opportunities are mediated by payer expectations, supply chain realities, and regional heterogeneity in access infrastructure. Stakeholders that align clinical development with pragmatic access planning and resilient manufacturing strategies will be best positioned to translate innovation into sustained patient benefit.

As the landscape continues to evolve, integrating real-world evidence, prioritizing biomarker-driven trials, and constructing flexible commercial models will be indispensable. The collective momentum toward more personalized and value-driven care offers a pathway to both improved clinical outcomes and optimized resource utilization, provided that sponsors, providers, and payers collaborate effectively to navigate the intricate interface between clinical promise and system-level feasibility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ovarian Cancer Drugs Market, by Cancer Type

  • 8.1. Epithelial Ovarian Cancer
  • 8.2. Germ Cell Tumors
  • 8.3. Small Cell Ovarian Cancer
  • 8.4. Stromal Cell Tumors

9. Ovarian Cancer Drugs Market, by Treatment Type

  • 9.1. Chemotherapy
  • 9.2. Hormonal Therapy
  • 9.3. Immunotherapy
  • 9.4. Radiation Therapy
  • 9.5. Targeted Therapy

10. Ovarian Cancer Drugs Market, by Therapeutic Class

  • 10.1. Angiogenesis Inhibitors
  • 10.2. PARP Inhibitors
  • 10.3. PD-L1 Inhibitors

11. Ovarian Cancer Drugs Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Ovarian Cancer Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Ovarian Cancer Drugs Market, by End User

  • 13.1. Cancer Centers
  • 13.2. Clinics
  • 13.3. Hospitals

14. Ovarian Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Ovarian Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Ovarian Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Ovarian Cancer Drugs Market

18. China Ovarian Cancer Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. Aravive, Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. Clovis Oncology, Inc.
  • 19.10. Compugen Ltd.
  • 19.11. GlaxoSmithKline plc
  • 19.12. ImmunoGen, Inc.
  • 19.13. Johnson & Johnson
  • 19.14. Merck & Co., Inc.
  • 19.15. Mersana Therapeutics, Inc.
  • 19.16. Novartis AG
  • 19.17. Oncxerna Therapeutics, Inc.
  • 19.18. Pfizer Inc.
  • 19.19. Regeneron Pharmaceuticals, Inc.
  • 19.20. Roche Holding AG
  • 19.21. Sutro Biopharma, Inc.
  • 19.22. Tesaro, Inc.
  • 19.23. Zentalis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY EPITHELIAL OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GERM CELL TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GERM CELL TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GERM CELL TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY SMALL CELL OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY SMALL CELL OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY SMALL CELL OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY STROMAL CELL TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY STROMAL CELL TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY STROMAL CELL TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GCC OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. G7 OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. NATO OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)